Spero Therapeutics to Provide Business Update and Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

Rhea-AI Summary

Spero Therapeutics, Inc. (Nasdaq: SPRO) will host a conference call on November 10, 2021, at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide updates on its business and pipeline. The company focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases. Spero's lead candidate, tebipenem HBr, is under review with a new drug application filed after positive Phase 3 trial results. Other developments include an oral therapy for NTM infections and an IV-administered polymyxin product for treating MDR infections.

Positive

• Successful filing of NDA for tebipenem HBr after positive Phase 3 trial results.
• Development of multiple product candidates targeting high unmet medical needs.

Negative

• Tebipenem HBr not yet approved for any indications.

CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that it will host a conference call and live audio webcast on Wednesday, November 10, 2021, at 4:30 p.m. ET to report its third quarter 2021 financial results and provide an update on its business and pipeline.

To access the call please dial 800-263-0877 (domestic) or 646-828-8143 (international) and refer to conference ID 5314099. The audio webcast can be accessed under “Events and Presentations” in the Investors and Media section of the Company’s website at www.sperotherapeutics.com. The archived webcast will also be available on Spero’s website for 30 days following the call.

About Spero Therapeutics
Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In October 2021, Spero filed a new drug application for tebipenem HBr, which included positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting.

Tebipenem HBr is currently not approved for the treatment of complicated urinary tract infection or acute pyelonephritis.

For more information, visit https://sperotherapeutics.com.

Investor Relations Contact:
Ted Jenkins
Vice President, Head of Investor Relations
Tjenkins@sperotherapeutics.com
(617) 798-4039

Media Contact: 
media@sperotherapeutics.com

FAQ

What are the upcoming events for Spero Therapeutics on November 10, 2021?

Spero Therapeutics will host a conference call to report its Q3 2021 financial results and business updates.

What is the focus of Spero Therapeutics?

Spero Therapeutics focuses on developing treatments for multi-drug resistant bacterial infections and rare diseases.

What is the status of tebipenem HBr from Spero Therapeutics?

Tebipenem HBr is currently under review with a new drug application filed, but it is not yet approved.

What other products is Spero developing besides tebipenem HBr?

Spero is developing SPR720 for NTM infections and SPR206 for MDR Gram-negative infections.